» Articles » PMID: 20208519

Transcription-independent ARF Regulation in Oncogenic Stress-mediated P53 Responses

Overview
Journal Nature
Specialty Science
Date 2010 Mar 9
PMID 20208519
Citations 93
Authors
Affiliations
Soon will be listed here.
Abstract

The tumour suppressor ARF is specifically required for p53 activation under oncogenic stress. Recent studies showed that p53 activation mediated by ARF, but not that induced by DNA damage, acts as a major protection against tumorigenesis in vivo under certain biological settings, suggesting that the ARF-p53 axis has more fundamental functions in tumour suppression than originally thought. Because ARF is a very stable protein in most human cell lines, it has been widely assumed that ARF induction is mediated mainly at the transcriptional level and that activation of the ARF-p53 pathway by oncogenes is a much slower and largely irreversible process by comparison with p53 activation after DNA damage. Here we report that ARF is very unstable in normal human cells but that its degradation is inhibited in cancerous cells. Through biochemical purification, we identified a specific ubiquitin ligase for ARF and named it ULF. ULF interacts with ARF both in vitro and in vivo and promotes the lysine-independent ubiquitylation and degradation of ARF. ULF knockdown stabilizes ARF in normal human cells, triggering ARF-dependent, p53-mediated growth arrest. Moreover, nucleophosmin (NPM) and c-Myc, both of which are commonly overexpressed in cancer cells, are capable of abrogating ULF-mediated ARF ubiquitylation through distinct mechanisms, and thereby promote ARF stabilization in cancer cells. These findings reveal the dynamic feature of the ARF-p53 pathway and suggest that transcription-independent mechanisms are critically involved in ARF regulation during responses to oncogenic stress.

Citing Articles

Genome-wide screening in human embryonic stem cells identifies genes and pathways involved in the p53 pathway.

Haddad A, Golan-Lev T, Benvenisty N, Goldberg M Mol Med. 2025; 31(1):97.

PMID: 40082762 PMC: 11907909. DOI: 10.1186/s10020-025-01141-5.


Helicobacter pylori activates DOPEY1 to promote p53 degradation through the USP7/TRIP12 axis in gastric tumorigenesis.

Zhou Y, Li N, Zhu Y, He Z, Ouyang Y, Ling L Oncogene. 2025; .

PMID: 39939725 DOI: 10.1038/s41388-025-03303-5.


DUX4-induced HSATII RNA accumulation drives protein aggregation impacting RNA processing pathways.

Arends T, Bennett S, Tapscott S bioRxiv. 2025; .

PMID: 39764024 PMC: 11702838. DOI: 10.1101/2024.12.17.628988.


The E3 Ubiquitin Ligase Trip12 attenuates Wnt9a/Fzd9b signaling during hematopoietic stem cell development.

Ensing J, Ide A, Gilliland C, Tsurho V, Caza I, Stratman A bioRxiv. 2024; .

PMID: 39484584 PMC: 11527353. DOI: 10.1101/2024.10.25.620301.


A ligand discovery toolbox for the WWE domain family of human E3 ligases.

Munzker L, Kimani S, Fowkes M, Dong A, Zheng H, Li Y Commun Biol. 2024; 7(1):901.

PMID: 39048679 PMC: 11269756. DOI: 10.1038/s42003-024-06584-w.


References
1.
Lowe S, Sherr C . Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev. 2003; 13(1):77-83. DOI: 10.1016/s0959-437x(02)00013-8. View

2.
Nozawa Y, van Belzen N, van der Made A, Dinjens W, Bosman F . Expression of nucleophosmin/B23 in normal and neoplastic colorectal mucosa. J Pathol. 1996; 178(1):48-52. DOI: 10.1002/(SICI)1096-9896(199601)178:1<48::AID-PATH432>3.0.CO;2-Y. View

3.
Li M, Brooks C, Wu-Baer F, Chen D, Baer R, Gu W . Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science. 2003; 302(5652):1972-5. DOI: 10.1126/science.1091362. View

4.
Bertwistle D, Sugimoto M, Sherr C . Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol Cell Biol. 2004; 24(3):985-96. PMC: 321449. DOI: 10.1128/MCB.24.3.985-996.2004. View

5.
Kuo M, den Besten W, Bertwistle D, Roussel M, Sherr C . N-terminal polyubiquitination and degradation of the Arf tumor suppressor. Genes Dev. 2004; 18(15):1862-74. PMC: 517406. DOI: 10.1101/gad.1213904. View